Samsara BioCapital related stories
All articles and analysis
Arcellx pulls in $115m Series CArcellx, a clinical-stage biopharmaceutical company, has raised $115 million in Series C financing.
- eGenesis fetches $125m Series C
eGenesis, a gene-editing and genome-engineering company, has closed $125 million in Series C financing.
Pipeline Therapeutics pulls in $80m Series CPipeline Therapeutics, a biopharmaceutical company, has secured $80 million in Series C financing.
Notch Therapeutics brings in $85m in Series A roundVancouver-based biotechnology company Notch Therapeutics has raised $85 million in a Series A financing.
- Samsara Biocapital targets $500m for fund
Samsara Biocapital is seeking to raise $500 million for its new fund, according to an SEC filing.
- Primmune Therapeutics amasses $27.4m Series A
San Diego-based Primmune Therapeutics, a biotech company, has raised $27.4 million in Series A financing.
- RayzeBio scores $45m Series A
San Diego-based RayzeBio Inc, a biotech company, has raised $45 million in Series A financing.
- A2 Biotherapeutics scores $71.5m Series B
Agoura Hills, California-based A2 Biotherapeutics, a developer of cell therapies for solid tumor cancer patients, has raised $71.5 million in Series B financing.
- Synthekine picks up $82m Series A
Menlo Park, California-based Synthekine Inc., an engineered cytokine therapeutics company, has raised $82 million in Series A financing.
- Graphite Bio snags $45m Series A
Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing.